Table 1.
Baseline clinicopathological characteristics in patients with EBV-positive DLBC.
| Characteristics | Whole-genome seq (n = 8) | Targeted seq (n = 39) | EBV-positive DLBCL (n = 47) |
|---|---|---|---|
| Age (yrs.; median + range) | 76.5 (68–83) | 69.5 (19–90) | 74.0 (19–90) |
| Sex | |||
| Female | 2 (25.0%) | 16 (41.0%) | 18 (38.3%) |
| Male | 6 (75.0%) | 23 (59.0%) | 29 (61.7%) |
| R-IPI | |||
| 0 | – | 4 (10.3%) | 4 (8.5%) |
| 1–2 | 5 (62.5%) | 21 (53.8%) | 26 (55.3%) |
| >2 | 3 (37.5%) | 19 (48.7%) | 22 (46.8%) |
| Stage (Ann Arbor) | |||
| I | 1 (12.5%) | 6 (15.4%) | 7 (14.9%) |
| II | 3 (37.5%) | 14 (35.9%) | 17 (36.2%) |
| III | 3 (37.5%) | 6 (15.4%) | 9 (19.1%) |
| IV | 1 (12.5%) | 13 (41.0%) | 14 (29.8%) |
| B-Symptoms | |||
| Yes | 3 (37.5%) | 21 (53.8%) | 24 (51.1%) |
| No | 5 (62.5%) | 18 (46.2%) | 23 (48.9%) |
| CD30 by immunohistochemistry | |||
| Positive | 7 (87.5%) | 29 (74.4%) | 36 (76.6%) |
| Negative | 1 (12.5%) | 10 (25.6%) | 11 (23.4%) |
| Extranodal sites | |||
| 0 | 6 (75.0%) | 16 (41.0%) | 22 (46.8%) |
| 1–2 | 2 (25.0%) | 23 (59.0%) | 25 (53.2%) |
| ECOG PS | |||
| 0–1 | 5 (62.5%) | 15 (38.5%) | 20 (42.6%) |
| ≥2 | 3 (37.5%) | 24 (61.5%) | 27 (57.4%) |
| LDH | |||
| Normal | 2 (25.0%) | 18 (46.2%) | 20 (42.6%) |
| Elevated | 6 (75.0%) | 21 (53.8%) | 27 (57.4%) |
| CNS involvement at diagnosis | |||
| Yes | – | 3 (7.7%) | 3 (6.4%) |
| No | 8 (100.0%) | 36 (92.3%) | 44 (93.6%) |
| Frontline therapy regimen | |||
| R-CHOP-like | 8 (100.0%) | 25 (64.1%) | 33 (70.2%) |
| R-based | 8 (100.0%) | 35 (89.7%) | 43 (91.5%) |
| Others | – | 2 (5.1%) | 2 (4.3%) |
| Refusal of treatment | – | 1 (2.6%) | 1 (2.1%) |
| Frontline therapy response rates | |||
| CR | 7 (87.5%) | 23 (59.0%) | 30 (63.8%) |
| PR | 1 (12.5%) | 10 (25.6%) | 11 (23,4%) |
| SD | – | 4 (10.3%) | 4 (8.5%) |
| PD | – | 2 (5.1%) | 2 (4.3%) |
EBV Epstein–Barr virus, Yrs. years, CNS central nervous system, LDH lactate dehydrogenase, ECOG Eastern cooperative oncology group, PS performance status, CHOP cyclophosphamide, doxorubicin, vincristine, prednisolone, R rituximab, Others other regimen (e.g., bendamustine) or palliative cytoreductive treatment.
Baseline characteristics of EBV + DLBCL (NOS) cases included in this study allocated according to affiliation to the discovery or the extension cohort, respectively.